LysoPS (lysophosphatidylserine) is a molecule that can inhibit T cell activation in the lab, and the enzyme (PS-PLA1) that produces lysoPS is upregulated in colorectal cancer. However, not much is known about this potential link between lysoPS and cancer, so Dr. Liu is exploring the signaling mechanisms and receptors that mediate lysoPS’s effects on T cells. To better define lysoPS’s molecular interactions and its effects on anti-cancer immune responses, Dr. Liu is investigating several target candidates—immune cell surface receptors—that appear to react with lysoPS. By characterizing the influence of lysoPS and the receptors it interacts with on T cell responses in the context of colorectal cancer, it could help guide approaches to mitigate any associated pro-cancer activity.
University of California, San Francisco | All Cancers, Breast Cancer, Colorectal Cancer, Melanoma | 2017 | Jason G. Cyster, Ph.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Meet three promising young scientists changing the face of immuno-oncology: Ryan K. Alexander, Ph.D., of Boston Children’s Hospital; Nelson M. LaMarche, Ph.D., of the Icahn School of Medicine at Mount Sinai; and Christopher B. Medina, Ph.D., of Emory University.
New research, new treatments, and how we’re working toward a future immune to cervical cancer